Terminology and Guidelines for Glaucoma
Download the EGS Guidelines on the European Glaucoma Society website.
Download the EGS Guidelines on the European Glaucoma Society website.
To compare visual field outcomes of ocular hypertensive and glaucoma patients treated first with medical therapy with those treated first with selective laser trabeculoplasty (SLT).
In recent years, the glaucoma treatment marketplace has been inundated with new laser technologies, which have excited physicians and surgeons as they have completely reinvented and invigorated the glaucoma treatment paradigm. Today, glaucoma is on the rise and continues to be one of the leading causes of blindness and vision loss worldwide.
Origins of surgical glaucoma treatment date
back to the mid 1800s when iridectomy was discovered as an effective surgical method for the treatment of acute glaucoma and sclerotomy was presented as a procedure for chronic glaucoma. Though advancements have continued to change the landscape of how to treat glaucoma, the approaches remain largely the same: relief of the pupillary block, external filtration, internal filtration, and ciliodestruction.
Glaucoma specialists have traditionally viewed topical therapy as first-line treatment for glaucoma. Recently, however, this paradigm has been challenged. Selective laser trabeculoplasty (SLT), though FDA approved since 2001, has gained acceptance as first-line treatment over the last 5 to 10 years.
The objective of this study was to compare the effectiveness and the tolerance of SS-TSCPC with a duty cycle of 25% versus 31.3% with Supra 810 nm Subliminal Quantel Medical laser stimulation for advanced glaucoma.
Glaucoma is a leading cause of irreversible blindness affecting approximately 60 million people globally 40 years of age and older. Glaucoma is a disease that cannot be ignored, and the need for significant changes in how we diagnose, manage, and treat must be examined and applied whenever possible.
The purpose of this study was to evaluate the efficacy and safety of subliminal cyclophotocoagulation using a 25% duty cycle diode laser (Supra 810, SubCyclo, Quantel Medical).
To analyse the results of subCyclo (subliminal transscleral cyclophotocoagulation) laser procedure for patients with glaucoma.
The glaucoma surgical landscape is bombarded with a variety of new microinvasive glaucoma surgery (MIGS) procedures daily. These new procedures are altering the paradigm and treatment concepts of glaucoma surgery and are accelerating the importance of earlier surgical intervention aimed at reducing morbidity of progression, reducing the need for more aggressive surgical options (while preserving those options), and reducing the burden of medication along with patientcompliance issues, which is one of the most prevalent problems in glaucoma treatment today.
Since 1993, Quantel Medical develops, manufactures and markets innovative medical laser and ultrasound solutions.
World leader in ophthalmology, its lasers and ultrasounds are designed to diagnose and treat the four main causes of blindness: cataracts, glaucoma, diabetic retinopathy and macular degeneration; and also dry eye disease.
"*" indicates required fields